Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California. Show more

Location: 1150 Veterans Boulevard, South San Francisco, CA, 94080, United States | Website: https://www.nkartatx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

138.5M

52 Wk Range

$1.31 - $5.67

Previous Close

$1.95

Open

$1.95

Volume

173,609

Day Range

$1.93 - $1.98

Enterprise Value

-72.65M

Cash

289.7M

Avg Qtr Burn

-24.42M

Insider Ownership

5.02%

Institutional Own.

86.47%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
NKX019 Details
Myasthenia gravis

Phase 1

Data readout

NKX019 (CAR NK cell therapy) Details
B-cell malignancies, Non-Hodgkin lymphoma, B-cell lymphoma

Phase 1

Data readout

NKX019 (CAR NK cell therapy) Details
Systemic lupus erythematosus, Autoimmune disease

Phase 1

Data readout

Phase 1

Data readout

NKX019 (CAR NK cell therapy) Details
Systemic sclerosis, Idiopathic inflammatory myopathy / myositis, ANCA-Associated Vasculitis

Phase 1

Data readout

NKX101 (CAR-T targeting NKG2D) Details
Bone marrow disorder, Acute myeloid leukemia, Cancer, Myelodysplastic syndrome

Failed

Discontinued